Wenzel Spine Reports 1st Cases with panaSIa SI Fusion, Begins Soft U.S. Launch

Wenzel Spine announced completion of the first cases and U.S. limited commercial launch of the panaSIa expandable SI (sacroiliac) fusion system.

According to the company, panaSIa is the first expandable SI fusion implant cleared by the FDA and is a major breakthrough in addressing SI joint dysfunction with enhance biomechanical stability and procedural efficiency. The device earned its FDA nod last month.

panaSIa is implanted in a posterior, minimally invasive approach. It offers joint fixation through controlled expansion across the ilium and sacrum, providing mechanical stability while preserving surrounding tissue. Its integrated graft chamber permits post-expansion bone grafting without disengaging instrumentation.

These first U.S. procedures are part of a limited commercial release at select surgical centers, ahead of a full launch in Q4 of this year. Aaron Calodney, MD, a nationally recognized leader in interventional pain medicine, said panaSIa is unlike any SI fusion device currently available.

“The implant expands to eliminate micro-motion, providing immediate stabilization,” Dr. Calodney told the press. “By slightly distracting the joint space, it may reduce pain by removing contact between the arthritic surfaces. It’s simple, elegant, and biomechanically sound—a truly next-generation solution for SI joint fusion.”

The system grows Wenzel’s portfolio of standalone expandable fusion technologies and reflects its commitment to minimally invasive innovation and surgeon-driven design.

“This launch is a defining milestone for Wenzel Spine,” said William Wilson, CEO of Wenzel Spine. “Our team has spent nearly two decades perfecting expandable device design, and panaSIa brings that legacy to a new clinical segment. We are proud to offer providers a differentiated, minimally invasive solution that transforms SI joint fusion with precision, control, and speed.”